Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary

Core Insights - The company views 2025 as a crucial year for building a foundation, focusing on enhancing financial flexibility and transitioning towards the $10 billion translational science market [1] - The evolution from a traditional tools provider to an enabler of translational science aims to address the high failure rate of drug candidates in human trials, which is currently at 90% [1] Financial Performance - Q4 performance showed a 27% year-over-year growth in adjusted EBITDA, driven by a favorable shift towards higher-margin product lines and disciplined expense management [1] - The strategic consolidation of manufacturing operations from Holliston to Minneapolis and European centers is projected to save $3 million in 2027 and $4 million annually thereafter [1] Revenue Strategy - The company is prioritizing higher-margin consumables, services, and software, which now account for approximately 55% of total revenue, to enhance visibility and sustainability [1] Governance and Leadership - Management has strengthened governance by appointing four new Board members and confirming Mark Frost as the permanent CFO to facilitate the transition to a platform-based technology provider [1]